Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 1/20 | 0.77 |
| ▸ | TGM2 | P21980 | 1/20 | 0.77 |
| ▸ | TGM1 | P22735 | 1/20 | 0.77 |
| ▸ | HSD11B1 | P28845 | 17/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3223739 | 0.90 | F13A1 (0.75) | F13A1TGM2TGM1HSD11B1CA12 | |
| SCHEMBL3224638 | 0.89 | F13A1 (0.73) | F13A1TGM2TGM1HSD11B1CA12 | |
| SCHEMBL1872122 | 0.87 | F13A1 (1.00) | F13A1TGM2TGM1HSD11B1CA12 | |
| SCHEMBL3213283 | 0.86 | CA12 (0.73) | F13A1TGM2TGM1HSD11B1CA12 | |
| SCHEMBL3224374 | 0.85 | CA12 (0.70) | F13A1TGM2TGM1HSD11B1CA12 | |
| SCHEMBL19248151 | 0.84 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL3210183 | 0.82 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL13031222 | 0.82 | HSD11B1 (0.84) | F13A1TGM2TGM1HSD11B1 | |
| SCHEMBL3604873 | 0.82 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL27756882 | 0.82 | HSD11B1 (0.80) | F13A1TGM2TGM1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | F13A1 3898/4885TGM2 2164/4885TGM1 2610/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | F13A1 3856/4885TGM2 2399/4885TGM1 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.